Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

James Michael Burke

TitlePost-Doctoral Fellow
InstitutionUniversity of Colorado Boulder
DepartmentBiochemistry

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Burke JM, Bass CR, Kincaid RP, Ulug ET, Sullivan CS. The Murine Polyomavirus MicroRNA Locus Is Required To Promote Viruria during the Acute Phase of Infection. J Virol. 2018 08 15; 92(16). PMID: 29875236.
      View in: PubMed
    2. Burke JM, Kincaid RP, Aloisio F, Welch N, Sullivan CS. Expression of short hairpin RNAs using the compact architecture of retroviral microRNA genes. Nucleic Acids Res. 2017 Sep 29; 45(17):e154. PMID: 28973449.
      View in: PubMed
    3. Burke JM, Sullivan CS. DUSP11 - An RNA phosphatase that regulates host and viral non-coding RNAs in mammalian cells. RNA Biol. 2017 11 02; 14(11):1457-1465. PMID: 28296624.
      View in: PubMed
    4. Burke JM, Kincaid RP, Nottingham RM, Lambowitz AM, Sullivan CS. DUSP11 activity on triphosphorylated transcripts promotes Argonaute association with noncanonical viral microRNAs and regulates steady-state levels of cellular noncoding RNAs. Genes Dev. 2016 09 15; 30(18):2076-2092. PMID: 27798849.
      View in: PubMed
    5. Burke JM, Kuny CV, Kincaid RP, Sullivan CS. Identification, validation, and characterization of noncanonical miRNAs. Methods. 2015 Dec; 91:57-68. PMID: 26210399.
      View in: PubMed
    6. Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, Patt R, Pelusio A, Burke J, Hwang TH, Kirn D, Park YS. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Mol Ther. 2015 Sep; 23(9):1532-40. PMID: 26073886.
      View in: PubMed
    7. Burke J, Nieva J, Borad MJ, Breitbach CJ. Oncolytic viruses: perspectives on clinical development. Curr Opin Virol. 2015 Aug; 13:55-60. PMID: 25989094.
      View in: PubMed
    8. Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Curr Opin Virol. 2015 Aug; 13:49-54. PMID: 25900822.
      View in: PubMed
    9. Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic Virother. 2015; 4:25-31. PMID: 27512667.
      View in: PubMed
    10. Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma. Methods Mol Biol. 2015; 1317:343-57. PMID: 26072416.
      View in: PubMed
    11. Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015 Mar; 23(3):602-8. PMID: 25531693.
      View in: PubMed
    12. Burke JM, Bass CR, Kincaid RP, Sullivan CS. Identification of tri-phosphatase activity in the biogenesis of retroviral microRNAs and RNAP III-generated shRNAs. Nucleic Acids Res. 2014 Dec 16; 42(22):13949-62. PMID: 25428356.
      View in: PubMed
    13. Chen CJ, Burke JM, Kincaid RP, Azarm KD, Mireles N, Butel JS, Sullivan CS. Naturally arising strains of polyomaviruses with severely attenuated microRNA expression. J Virol. 2014 Nov; 88(21):12683-93. PMID: 25142594.
      View in: PubMed
    14. Burke JM, Kelenis DP, Kincaid RP, Sullivan CS. A central role for the primary microRNA stem in guiding the position and efficiency of Drosha processing of a viral pri-miRNA. RNA. 2014 Jul; 20(7):1068-77. PMID: 24854622.
      View in: PubMed
    15. Kincaid RP, Burke JM, Cox JC, de Villiers EM, Sullivan CS. A human torque teno virus encodes a microRNA that inhibits interferon signaling. PLoS Pathog. 2013; 9(12):e1003818. PMID: 24367263.
      View in: PubMed
    16. Seo GJ, Kincaid RP, Phanaksri T, Burke JM, Pare JM, Cox JE, Hsiang TY, Krug RM, Sullivan CS. Reciprocal inhibition between intracellular antiviral signaling and the RNAi machinery in mammalian cells. Cell Host Microbe. 2013 Oct 16; 14(4):435-45. PMID: 24075860.
      View in: PubMed
    17. McClure LV, Kincaid RP, Burke JM, Grundhoff A, Sullivan CS. Comprehensive mapping and analysis of Kaposi's sarcoma-associated herpesvirus 3' UTRs identify differential posttranscriptional control of gene expression in lytic versus latent infection. J Virol. 2013 Dec; 87(23):12838-49. PMID: 24067953.
      View in: PubMed
    18. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013 Mar; 19(3):329-36. PMID: 23396206.
      View in: PubMed
    19. Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013 Feb 15; 73(4):1265-75. PMID: 23393196.
      View in: PubMed
    20. Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7. PMID: 23088985.
      View in: PubMed
    21. Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul 10; 30(20):2516-21. PMID: 22614993.
      View in: PubMed
    22. Kincaid RP, Burke JM, Sullivan CS. RNA virus microRNA that mimics a B-cell oncomiR. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):3077-82. PMID: 22308400.
      View in: PubMed
    23. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011 Aug 31; 477(7362):99-102. PMID: 21886163.
      View in: PubMed
    24. Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011 Oct; 19(10):1913-22. PMID: 21772252.
      View in: PubMed
    25. Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 2010 Apr-Jun; 21(2-3):85-9. PMID: 20472490.
      View in: PubMed
    26. Burke J. Virus therapy for bladder cancer. Cytokine Growth Factor Rev. 2010 Apr-Jun; 21(2-3):99-102. PMID: 20382064.
      View in: PubMed
    27. Burke JM. GM-CSF-armed, replication-competent viruses for cancer. Cytokine Growth Factor Rev. 2010 Apr-Jun; 21(2-3):149-51. PMID: 20381405.
      View in: PubMed
    28. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y, Fujiwara T. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010 Feb; 18(2):429-34. PMID: 19935775.
      View in: PubMed
    29. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008 Mar 01; 14(5):1455-63. PMID: 18316569.
      View in: PubMed
    30. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17. PMID: 16690359.
      View in: PubMed
    31. Higgins RS, Bridges J, Burke JM, O'Donnell MA, Cohen NM, Wilkes SB. Implementing the ACGME general competencies in a cardiothoracic surgery residency program using 360-degree feedback. Ann Thorac Surg. 2004 Jan; 77(1):12-7. PMID: 14726026.
      View in: PubMed
    Burke's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)